Patents by Inventor Lars Rymo

Lars Rymo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
    Patent number: 5840313
    Abstract: Novel peptides are disclosed which correspond to epitopes of the HIV-1 gp120 protein. These antigenic peptides induce antibody-dependent cellular cytotoxicity against HIV, and thus are useful in immunization against HIV infection and induction of a heightened immune response to HIV.
    Type: Grant
    Filed: June 20, 1995
    Date of Patent: November 24, 1998
    Assignee: Syntello Vaccine Development KB
    Inventors: Anders Vahlne, Bo Syennerholm, Lars Rymo, Stig Jeansson, Peter Horal
  • Peptides for detecting antibodies to HTLV-2
    Patent number: 5670311
    Abstract: Peptides corresponding to epitopes of HTLV-2 proteins are provided. These peptides are immunologically reactive with HTLV-2 specific antibodies. Several of the peptides are sufficiently unreactive to antibodies to HTLV-1 to distinguish between antibodies which recognize HTLV-1 and those which recognize HTLV-2. Thus HTLV-1 infections can be distinguished from HTLV-2 infections. The peptides are useful in assays for detection of HTLV-2 infection or exposure. The peptides are also useful as vaccine compositions against HTLV-2. Antibodies generated in response to immunization by the peptides are also provided.
    Type: Grant
    Filed: April 17, 1995
    Date of Patent: September 23, 1997
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Anders Vahlne, Bo Svennerholm, Lars Rymo, Stig Jeansson, Peter Horal
  • Peptides that block human immunodeficiency virus and methods of use thereof
    Patent number: 5627035
    Abstract: It has now been found that relatively short peptides such as the tripeptide glycyl-prolyl-glycine are able to effectively inhibit HIV infection of cells and syncytia formation between HIV infected and and non-infected cells. The peptides are suitable for therapy of patients infected with HIV and in prevention of HIV infection.
    Type: Grant
    Filed: June 26, 1995
    Date of Patent: May 6, 1997
    Assignee: Syntello Vaccine Development AB
    Inventors: Anders Vahlne, Bo Svennerholm, Lars Rymo, Peter Horal, Stig Jeansson
  • Peptides for induction of neutralizing antibodies against human immunodeficiency virus
    Patent number: 5589175
    Abstract: In accordance with the present invention, novel peptides corresponding to epitopes of human immunodeficiency virus-1 gp120 protein and analogues and homologs thereof are provided. These peptides can be utilized alone or in combination, uncoupled or coupled to other molecules or substrates. The peptides are useful in immunization against human immunodeficiency virus infection and in production of polyclonal and monoclonal antibodies.
    Type: Grant
    Filed: March 27, 1995
    Date of Patent: December 31, 1996
    Assignee: Syntello Vaccine Development KB
    Inventors: Anders Vahlne, Bo Svennerholm, Lars Rymo, Stig Jeansson, Peter Horal
  • Peptides for use in induction of T cell activation against HIV-1
    Patent number: 5346989
    Abstract: Peptides corresponding to regions of the human immunodeficiency virus protein gp-120 are provided for eliciting T-cell activation.
    Type: Grant
    Filed: September 13, 1993
    Date of Patent: September 13, 1994
    Assignee: Syntello Vaccine Development KB
    Inventors: Anders Vahlne, Bo Svennerholm, Lars Rymo, Stig Jeansson, Peter Horal, Cecil Czerkinsky, Jan Holmgren
  • Peptides for HTLV-2 infection diagnosis of, therapy for, vaccination against, for distinguishing between HTLV-1 and HTLV-2 infections and antibodies derived therefrom
    Patent number: 5283320
    Abstract: Peptides corresponding to epitopes of HTLV-2 proteins are provided. These peptides are immunologically reactive with HTLV-2 specific antibodies. Several of the peptides are sufficiently unreactive to antibodies to HTLV-1 to distinguish between antibodies which recognize HTLV-1 and those which recognize HTLV-2. Thus HTLV-1 infections can be distinguished from HTLV-2 infections. The peptides are useful in assays for detection of HTLV-2 infection or exposure. The peptides are also useful as vaccine compositions against HTLV-2. Antibodies generated in response to immunization by the peptides are also provided.
    Type: Grant
    Filed: November 13, 1989
    Date of Patent: February 1, 1994
    Assignee: Syntello AB
    Inventors: Anders Vahlne, Bo Svennerholm, Lars Rymo, Stig Jeansson, Peter Horal
  • Peptides for the detection of HTLV-1 infection
    Patent number: 5017687
    Abstract: Four peptides corresponding to regions of the glycoprotein encoded by the env gene of HTLV1 are provided. These peptides which are immunologically reactive with HTLV-1 specific antibodies are useful in assays for detection of HTLV-1 infection or exposure and in compositions to elicit the production of antibodies against HTLV-1 in animals and man.
    Type: Grant
    Filed: June 13, 1988
    Date of Patent: May 21, 1991
    Assignee: Virovahl, S.A.
    Inventors: Anders Vahlne, Bo Svennerholm, Lars Rymo, Stig Jeansson, Peter Horal
  • Synthetic peptide antigen for the detection of HIV-2 infection
    Patent number: 4812556
    Abstract: A synthetic peptide antigen corresponding to a region of the glycoprotein gp41 encoded by the env gene of HIV-2 is provided. The peptide which is immunologically reactive with HIV-2 specific antibodies is useful in assays for detection of HIV-2 infection or exposure and in compositions to elicit the production of antibodies against HIV-2 in animals including man.
    Type: Grant
    Filed: May 18, 1987
    Date of Patent: March 14, 1989
    Assignee: Virovahl
    Inventors: Anders Vahlne, Bo Svennerholm, Lars Rymo, Stig Jeansson, Peter Horal